Author: Ravi Shankar

• Built on approximately $1.7 billion in historical infrastructure investment with estimated replacement value over $3.2 billion. Pronghorn combines nearly 100 MMcf/day of gross gas production, more than 450 miles of owned pipelines, and approximately 1,000,000 acres of private, state, and BLM mineral and leasehold interests. Current gas output is estimated to be sufficient to fuel up to approximately 600 MW of gas-fired generation, depending on plant efficiency.
• Positions GridAI in Wyoming’s emerging AI data center market. Combining an established energy business, substantial water resources, and access to large-scale land development opportunities to support multi-gigawatt campus development potential. Pronghorn also produces nearly 14 million gallons of fresh water daily.
• Targeting 300 MW of initial power delivery in 2027. Multiple grid-connected large load capable substations on Pronghorn’s already identified multi-thousand-acre data center sites. Develop dedicated behind-the-meter (“BTM”) natural gas fired power generation in phases to serve hyperscale customers and reduce reliance on conventional utility interconnection timelines.
• Pursue value from gas sales, power contracts, water supply, and AI campus ownership. Preserve the upstream business’s standalone economics while pursuing long-term power supply agreements and meaningful ownership interests in the data center campuses GridAI helps develop.
• Acquire exclusive 1st American Nuclear Co. (“FANCO”) Wyoming rights for the EAGL-1 240 MWe SMR platform and Bridge Power, subject to commercial availability and regulatory approvals.

BOCA RATON, Fla. and SHERIDAN, Wyo., Nov. 13, 2026 (GLOBE NEWSWIRE) — GridAI Technologies Corp. (Nasdaq: GRDX) (“GridAI” or the “Company”) today announced it has entered into a Definitive Share Exchange Agreement to acquire Pronghorn Resources LLC (“Pronghorn”), a substantial producing natural gas and energy infrastructure platform in Wyoming’s Powder River Basin, establishing the foundation for a vertically integrated provider of dedicated power and infrastructure to the rapidly expanding artificial intelligence and hyperscale data center industries.

“Reliable power is the critical constraint on AI infrastructure growth. Pronghorn gives us the fuel, infrastructure, and operating foundation to address that need at scale in Wyoming,” said Jason Sawyer, Chief Executive Officer of GridAI Technologies Corp. “Our strategy is to build value from natural gas production and sales, pursue long-term power supply agreements, and use our land, water, and infrastructure assets to secure meaningful ownership interests in the AI campuses we partner to develop. We are targeting initial power delivery in 2027, with phased expansion aligned to customer commitments, financing, and project approvals. Our goal is to turn an established energy business into a scalable power and infrastructure platform that serves hyperscale customers and creates durable value for GridAI shareholders.”

The acquisition combines an established natural gas operating business with approximately 100 million cubic feet per day of gross natural gas production, nearly 2 trillion cubic feet (Tcf) of estimated gas reserves, almost 1,000,000 acres of mineral and leasehold interests, more than 450 miles of owned pipeline infrastructure, significant water resources, a 190 full-time combined contracted and direct workforce, and access to large-scale land development opportunities. Multiple sites have been identified that are suitable for utility-scale power development and data center campuses, each located within two unincorporated, mining, industrial, and energy-friendly counties.

Pronghorn’s existing energy infrastructure represents approximately $1.7 billion in historical capital expenditure, providing GridAI with an extensive installed asset base that would require very substantial time, capital, and effort to replicate.

GridAI intends to leverage these assets to develop reliable, dispatchable BTM electric power, supplemented by grid-connected or grid-supported infrastructure where appropriate, for hyperscale AI computing campuses.

The Company is targeting initial power delivery during 2027, with a phased development strategy intended to accelerate deployment while reducing reliance on conventional utility interconnection timelines.

Wyoming’s Emergence as a Strategic AI Infrastructure Destination
The acquisition comes at a pivotal moment for American AI infrastructure development.

The November 2026 U.S. midterm elections highlighted growing political and community resistance to large-scale data center development in numerous jurisdictions. According to Ballotpedia, voters favored limiting or opposing data center development in 40 of 41 local ballot measure contests nationwide.

At the same time, Wyoming is attracting major investment in AI infrastructure, supported by substantial domestic energy resources, established industrial infrastructure, a favorable business environment, and a state-level framework for responsible development.

On November 5, 2026, Google announced a $17 billion investment in its first Wyoming data center, incorporating a major natural gas-powered electricity generation initiative and partnerships with established energy and infrastructure companies.

GridAI believes this announcement reinforces Wyoming’s emergence as a destination for energy-intensive AI computing infrastructure and validates the strategic importance of developing dedicated power resources alongside hyperscale data center campuses.

Wyoming Governor Mark Gordon has established a statewide development framework through the executive order Data Centers the Wyoming Way, emphasizing regulatory coordination, economic development, responsible resource management, and protection of existing electricity customers.

Governor-elect Eric Barlow has likewise indicated support for responsible data center development in Wyoming, while emphasizing that projects should protect local water resources, cover their own energy costs and deliver benefits to host communities. GridAI believes its dedicated-generation approach is consistent with those priorities.

GridAI believes its strategy aligns with this evolving policy environment by emphasizing dedicated generation, domestic fuel resources, existing industrial infrastructure, and the ability to reduce incremental demands on conventional utility systems.

The Company believes Wyoming’s combination of energy availability, land, infrastructure, and constructive state-level policy could position it as one of America’s most important emerging markets for large-scale AI infrastructure investment.

An Existing, Producing Energy Platform
Unlike greenfield infrastructure developments that must independently assemble land, fuel supply, transportation infrastructure, water resources, and other essential components, Pronghorn brings an established operating energy business and substantial existing infrastructure.

• Current Natural Gas Production: Approaching 100 million cubic feet per day (100 MMcf/day) of current gross natural gas production, enough gas to fuel up to approximately 600 MW of gas-fired power generation, The 600 MW equivalency is an indicative fuel-to-power calculation, not currently installed generating capacity, and is subject to generator efficiency, operating conditions, and continuity of deliverable gas volumes.
• Existing Well Infrastructure: Approximately 3,200 producing natural gas wells supported by established field operations.
• Production Expansion: An ongoing well workover and rehabilitation program, together with planned new drilling activity, intended to increase production and support expanding power requirements.
• Natural Gas Reserves: Approximately 2 Tcf of 3P estimated natural gas reserves.
• Mineral and Leasehold Interests: Approximately 1,000,000 acres across Wyoming’s Powder River Basin.
• Owned Pipeline Infrastructure: More than 450 miles of natural gas gathering and pipeline infrastructure, compression facilities, and connectivity to major regional transportation systems, including Kinder Morgan and Western Midstream.
• Owned Water Resources: Nearly 14 million gallons (approximately 330,000 barrels) of daily water production, representing a substantial existing resource with potential industrial and data center cooling applications.
• Historical Infrastructure Investment: Approximately $1.7 billion in historical capital expenditure associated with the owned energy infrastructure, including pipeline, gathering, compression, and related operating assets.
• Land and Connectivity: Significant land development opportunities, existing energy infrastructure, and access to regional high-capacity fiber connectivity.

These assets provide the foundation for GridAI’s fuel-native, integrated energy and AI infrastructure development strategy.

Fuel Certainty and Speed to Power: Targeting 2027
GridAI believes access to reliable, scalable electricity has become one of the principal constraints on the development of large-scale AI computing infrastructure.

The Company’s strategy is designed to address this challenge through dedicated natural gas-fired generation supported by Pronghorn’s existing production, reserves, and transportation infrastructure.

By integrating fuel production and power development, GridAI seeks to provide High Performance Compute, data center offtake partners with greater certainty regarding long-term energy availability, competitive generation economics, and accelerated deployment schedules.

The Company’s existing natural gas production also represents an operating business with independent commercial value, allowing GridAI to pursue additional power generation opportunities while preserving the economics of its upstream operations.

GridAI intends to develop power infrastructure in phases, targeting initial delivery in 2027 and subsequent expansion to support multi-gigawatt hyperscale AI development opportunities.

Grid-connected or grid-supported infrastructure may complement dedicated behind-the-meter generation where appropriate, providing additional operating flexibility and resilience.

Integrated Power Platform: FANCO Bridge Power and Advanced Nuclear
In connection with the Pronghorn acquisition, GridAI entered into an agreement with Sigma9 Capital Ltd. to acquire, by assignment effective upon the closing of the Pronghorn acquisition, exclusive FANCO Wyoming development rights under Sigma9’s joint venture agreement with FANCO, establishing an expanded framework for energy infrastructure projects throughout the state.

Central to the longer-term development strategy is FANCO’s Bridge Power platform, designed to enable accelerated deployment of reliable, dispatchable electricity generation ahead of eventual small modular reactor (“SMR”) deployment of 240 MWe units ultimately designed for baseload power of 1.44 MWe in a 6-unit cluster.

The Bridge Power approach is intended to support initial electricity delivery using commercially available generation technologies while establishing the infrastructure and development framework for the subsequent integration of advanced nuclear power.

Rather than requiring a wholesale replacement of existing generation assets, the strategy envisions an additive transition, in which SMR capacity can be introduced alongside operating generation infrastructure as the technology becomes commercially available and receives the necessary regulatory approvals.

This approach is intended to provide customers with near-term power availability, continuity of operations, long-term generation flexibility, and a potential pathway toward a lower-carbon energy mix.

GridAI’s immediate focus remains commercially available natural gas generation and targeted initial power delivery in 2027. Advanced nuclear generation represents a complementary longer-term development opportunity.

Carbon Capture and Geological Sequestration Potential
Beyond its existing natural gas production and infrastructure, GridAI believes the Powder River Basin offers a potentially significant additional advantage: substantial geological capacity for long-term carbon dioxide sequestration.

The basin’s extensive history of natural gas production, including coalbed methane extraction, provides opportunities to evaluate depleted and suitable subsurface formations for potential carbon storage.

U.S. Department of Energy-supported research has estimated that un-mineable coal seams within the Powder River Basin could potentially accommodate approximately 14 billion metric tons of carbon dioxide, identifying the region as a significant geological carbon storage opportunity.

GridAI intends to evaluate the integration of carbon capture and geological sequestration with its planned natural gas-fired power generation infrastructure, leveraging Pronghorn’s extensive subsurface interests and existing energy operations.

The Company believes the potential combination of dedicated natural gas generation, carbon capture and storage, and eventual advanced nuclear deployment could create a differentiated long-term power platform capable of addressing both the reliability requirements and evolving environmental objectives of hyperscale AI customers.

Any future sequestration activities would remain subject to geological evaluation, reservoir characterization, applicable permits, engineering, and commercial feasibility. Basin-wide estimates do not establish storage capacity attributable to Pronghorn’s specific assets.

Transaction Terms
Under the share exchange agreement, the members of Pronghorn will exchange all outstanding membership units of Pronghorn for 1,247,887 shares of GridAI common stock and up to 129,504 shares of newly designated Series I Convertible Preferred Stock, including 13,200 shares to be held in escrow to secure indemnification obligations and 6,600 shares issuable upon achievement of a well workover milestone, subject to adjustment. Conversion is subject to GridAI stockholder approval, Nasdaq approval of the listing of the conversion shares, and a beneficial ownership limitation. As consideration for the assignment of the exclusive FANCO Wyoming rights, GridAI will issue to Sigma9 Capital Ltd. 794,109 shares of common stock and 82,411 shares of Series I Convertible Preferred Stock, subject to adjustment. The shares issued in the transactions will be subject to 30-month lock-up agreements. Series I holders will receive registration rights, with the Pronghorn members receiving the right to designate one director to GridAI’s Board of Directors at closing. The transaction is anticipated to close on or before November 22, 2026.

Additional details and terms of the transaction will be set forth in a Current Report on Form 8-K to be filed by GridAI with the U.S. Securities and Exchange Commission (SEC).

About GridAI Technologies Corp.
GridAI Technologies Corp. (Nasdaq: GRDX) is developing a vertically integrated energy and infrastructure platform designed to support the expanding power requirements of artificial intelligence, high-performance computing, and hyperscale data centers.

Through its Wyoming operations, the Company seeks to combine natural gas production, dedicated electric generation, land, water, and existing infrastructure to accelerate the deployment of large-scale American AI infrastructure.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, to the extent applicable.

Forward-looking statements include, without limitation, statements regarding GridAI Technologies Corp.’s (the “Company”) strategy, plans, objectives, expectations, and future operations; the anticipated strategic and economic benefits of the acquisition of Pronghorn Resources and the exclusive FANCO Wyoming development rights; the integration and expansion of the acquired operations; future natural gas production, well rehabilitation, drilling programs, reserve development and fuel availability; the potential generation capacity supported by the Company’s natural gas resources; the development of dedicated behind-the-meter and grid-supported power generation infrastructure; the Company’s target of initial power delivery in 2027; future hyperscale AI data center development opportunities; potential power supply agreements, customer relationships, joint ventures, and ownership interests; the implementation of FANCO’s Bridge Power strategy; the potential future deployment of small modular reactors and other advanced nuclear technologies; and the potential development and commercial viability of carbon capture and geological sequestration.

These forward-looking statements are generally identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will,” “would,” “could,” “estimate,” “seek,” and similar expressions. Such statements are based on management’s current expectations, assumptions, and information available as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

These risks and uncertainties include, among others: the Company’s ability to successfully integrate and operate the acquired assets; fluctuations in natural gas prices and operating costs; the timing, cost, and success of planned well rehabilitation, drilling, and production expansion activities; uncertainties concerning the future recoverability, production rates, and deliverability of natural gas reserves; the availability and capacity of pipelines, compression facilities, water resources, and other infrastructure; the Company’s ability to obtain financing on acceptable terms; the availability and cost of power generation equipment, contractors, and other development resources; the timing and receipt of required permits and regulatory approvals; potential delays, cost overruns, or other challenges in developing power generation and data center infrastructure; the Company’s ability to achieve targeted power delivery dates or generation capacities; the negotiation and execution of definitive customer, power supply, development, and joint venture agreements; and the realization of anticipated economic benefits from such arrangements.

Additional risks include the scope, implementation, and commercial value of the acquired FANCO Wyoming rights; the technical, commercial, licensing, and regulatory uncertainties associated with small modular reactors and other advanced nuclear technologies; the geological suitability, technical feasibility, permitting requirements, costs, and commercial viability of carbon capture and sequestration; changes in energy markets, environmental requirements, federal, state, or local laws and policies; and broader economic, competitive, and capital market conditions.

There can be no assurance that the Company’s planned power generation or data center projects will be completed, that initial power delivery will occur in 2027, that future SMR or carbon sequestration projects will be developed or become commercially viable, or that anticipated customer agreements, project ownership interests, or other commercial opportunities will be realized.

Additional factors that could cause actual results to differ materially from those contemplated by forward-looking statements are described in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”), including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and subsequent filings available at www.sec.gov.

Forward-looking statements speak only as of the date of this press release and are not guarantees of future performance. Readers should not place undue reliance on these statements. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect subsequent events or circumstances.

Investor Relations:
Jason Assad IR@gridaipower.com
(678) 570-6791
Website: https://gridaipower.com

• $100 million license awarded from U.S. Department of Commerce for sale and export of recycled black mass product
• Major milestone achieved with federal permitting for ABTC’s Tonopah Flats Lithium Project, one of the largest identified critical mineral lithium projects in the U.S.
• Company demonstrates strong cash position along with zero debt

RENO, Nev., Nov. 13, 2026 (GLOBE NEWSWIRE) — American Battery Technology Company (NASDAQ: ABAT), an integrated domestic critical mineral manufacturing company that is commercializing its internally-developed technologies for both primary critical mineral manufacturing and secondary critical mineral recycling, released the financial results for its first quarter of fiscal year 2027 ended on September 30, 2026.

Financial Highlights, First Quarter of FY27:

• $1.7 million in Revenue, an 83% increase from the same quarter the previous year
  • An additional $0.4 million recorded as interest income for the quarter
  • Substantial increase in finished goods inventory, from the continued commercial scale operations of recycling facility but with the accumulation of product due to temporary federal export ban
• $5.4 million in Cost of Goods Sold, an only 20% increase from the same quarter the previous year
  • Resulting from implementation of multiple operational efficiencies
• $43.4 million cash, including $0.1 million in restricted cash
• $0.0 million debt, Company currently holds zero debt

Over the quarter, American Battery Technology Company (ABTC) continued to scale-up and implement operational efficiencies at its Nevada critical mineral recycling facility. While the commercial facility continued operations throughout the quarter, on August 6, 2026, the U.S. Department of Commerce’s Bureau of Industry and Security (BIS) issued a directive in the federal register that it was restricting the export of black mass from recycled battery materials effective August 27, 2026. Recycled black mass is the primary product from ABTC’s critical mineral recycling facility, and essentially all of this product is exported for sale.

ABTC submitted an exception request for a license to continue to export black mass throughout the approximately one-year duration of this export restriction, and on September 30, 2026, the BIS issued such a license to ABTC. This temporary restriction of the export of black mass resulted in a large accumulation of finished goods inventory within the quarter, and limited sale and recognition of revenue within Q1 FY27. Subsequent to the conclusion of this reporting period, ABTC restarted the large-scale sale and exportation of accumulated black mass product, along with the sale of product made within Q2 to date.

“We are excited to have been issued this license and to now be selling the black mass produced within Q1 FY27 along with the black mass we are currently producing and are grateful to our multiple stakeholders and champions who supported us during this process,” stated American Battery Technology Company CEO Ryan Melsert. “We are proud of the strong relationships we have built within multiple agencies throughout the U.S. government and across multiple administrations.”

In addition to operating its critical mineral recycling facility, ABTC is also developing its critical mineral mine and refinery at its Tonopah Flats Lithium Project (TFLP) near Tonopah, Nevada. During the quarter ABTC announced that it has received acceptance of its Plan of Operations by the U.S. BLM for the construction and operations of its TFLP, which is a major milestone in the commercialization of one of the largest identified critical mineral lithium resources in the United States.

Description ($M)	Q1 FY27 Ended September 30, 2026		Q1 FY26 Ended September 30, 2025		Change
Revenue	$ 1.7		$ 0.9		83%
Cost of goods sold	$ (5.4)		$ (4.5)		20%
Gross profit (loss)	$ (3.6)		$ (3.5)		4%

Critical Mineral Recycling Highlights: Continued and Expanded Sales of Products

• Receipt of license for the export of up to $100 million of recycled black mass product to strategic customers
• Implementation of operational effectiveness of recycling operations, resulting in significant cost savings
• Continued processing of high-value recycled products from Battery Energy Storage Systems (BESS) supporting datacenters and artificial intelligence (AI) facilities, end-of-life electric and hybrid vehicles, and consumer electronics
• As one of the few recyclers in the Western U.S capable of handling CERCLA-classified waste, ABTC’s Nevada lithium-ion battery recycling facility, permitted by the EPA in Spring 2025 under CERCLA, has emerged as a critical revenue engine recovering valuable metals from high-demand, hard-to-recycle battery sources
• Continued development for the establishment of our second critical mineral recycling facility in the Southeast U.S., with plans to substantially scale capacity compared to company’s existing recycling plant in Nevada, positioning the company for expanded, matched-market impact
• The establishment of new supply chain partnerships with leading BESS facilities and automotive OEMs, providing near-term and long-term material flows to support the company’s growing operations

Primary Lithium from Claystone Highlights: Accelerating a Domestic Supply Chain

• ABTC’s Tonopah Flats Lithium Project (TFLP), one of the largest lithium deposits in the U.S., continues to secure its position as a cornerstone of the domestic critical mineral supply chain to support demand and drive future growth
• ABTC received a notice that its mine and refinery Plan of Operations was accepted by the U.S. Bureau of Land Management (BLM), marking a major milestone in project commercialization
• ABTC successfully won its appeal and had full reinstatement of its $57 million competitive grant from the U.S. Department of Energy supporting the $115 million construction of the first processing train at the TFLP
• ABTC has successfully advanced its claystone-to-lithium hydroxide demonstration plant and is now focused on scaling through construction of a full-scale commercial mine and refinery
• Designated as a Fast-41Transparency Covered Project under federal initiatives to boost and onshore domestic critical mineral supply, the TFLP benefits from streamlined federal permitting efforts, accelerating its path to commercialization of a new U.S. lithium resource and domestic production of critical mineral lithium hydroxide
• The company achieved a critical milestone by completing and submitting all baseline studies for the National Environmental Policy Act (NEPA) review process, a multi-year effort overseen by the Department of Interior’s Bureau of Land Management (BLM), involving over 40 regulatory agencies and stakeholders across 21 study areas
• The company has initiated its Definitive Feasibility Study, the final phase of engineering and financial analysis required to move the project into commercial production, with recommendations published in its September 2025 Pre-Feasibility Study (PFS)
  • Designed production of 30,000 tonnes per year of lithium hydroxide monohydrate (LHM), with project economics calculated for a 45-year life-of-mine
  • After-tax NPV at 8% of $2.57 billion and IRR of 21.8%, underscoring its financial viability
  • Highly competitive production cost of $4,307 per tonne, representing a 9.2% reduction from the company’s April 2024 Initial Assessment
  • Total TFLP lithium resources (measured, indicated, and inferred) increased approximately 11% to 21.3 million tonnes LHM, and establishment of 2.73 million tonnes of proven (0.98) and probable (1.75) reserves, compared to April 2024 Initial Assessment

ABTC hosted its Annual Shareholder Meeting yesterday, providing shareholders with an update on the company’s progress, strategic priorities, and continued advancement of its critical mineral recycling and primary lithium initiatives. A recording of the webcast within 24 hours will be available at Virtualshareholdermeeting.com/ABTC2026 or on ABTC’s Earnings & Events page.

About American Battery Technology Company 
American Battery Technology Company (ABTC), headquartered in Reno, Nevada, has pioneered first-of-kind technologies to unlock domestically manufactured and recycled battery metals critically needed to help meet the significant demand from the electric vehicle, stationary storage, and consumer electronics industries. Committed to a circular supply chain for battery metals, ABTC works to continually innovate and master new battery metals technologies that power a global transition to electrification and the future of sustainable energy.

Inferred Resource
Inferred Mineral Resource is that part of a mineral resource for which quantity and grade or quality are estimated on the basis of limited geological evidence and sampling. The level of geological uncertainty associated with an Inferred Mineral Resource is too high to apply relevant technical and economic factors likely to influence the prospects of economic extraction in a manner useful for evaluation of economic viability. Because an Inferred Mineral Resource has the lowest level of geological confidence of all mineral resources, which prevents the application of the modifying factors in a manner useful for evaluation of economic viability, an Inferred Mineral Resource may not be considered when assessing the economic viability of a mining project, and may not be converted to a mineral reserve.

Indicated Resource
Indicated Mineral Resource is that part of a mineral resource for which quantity and grade or quality are estimated on the basis of adequate geological evidence and sampling. The level of geological certainty associated with an Indicated Mineral Resource is sufficient to allow a qualified person to apply modifying factors in sufficient detail to support mine planning and evaluation of the economic viability of the deposit. Because an Indicated Mineral Resource has a lower level of confidence than the level of confidence of a Measured Mineral Resource, an Indicated Mineral Resource may only be converted to a Probable Mineral Reserve.

Measured Resource
Measured Mineral Resource is that part of a mineral resource for which quantity and grade or quality are estimated on the basis of conclusive geological evidence and sampling. The level of geological certainty associated with a Measured Mineral Resource is sufficient to allow a qualified person to apply modifying factors, as defined in this section, in sufficient detail to support detailed mine planning and final evaluation of the economic viability of the deposit. Because a Measured Mineral Resource has a higher level of confidence than the level of confidence of either an Indicated Mineral Resource or an Inferred Mineral Resource, a Measured Mineral Resource may be converted to a Proven Mineral Reserve or to a Probable Mineral Reserve.

Mineral Reserve
Mineral Reserve is an estimate of tonnage and grade or quality of indicated and measured mineral resources that, in the opinion of the qualified person, can be the basis of an economically viable project. More specifically, it is the economically mineable part of a measured or indicated mineral resource, which includes diluting materials and allowances for losses that may occur when the material is mined or extracted.

Probable Mineral Reserve
Probable Mineral Reserve is the economically mineable part of an indicated and, in some cases, a measured mineral resource.

Proven Mineral Reserve
Proven Mineral Reserve is the economically mineable part of a measured mineral resource and can only result from conversion of a measured mineral resource.

Pre-Feasibility Study
A Preliminary Feasibility Study (or Pre-Feasibility Study) is a comprehensive study of a range of options for the technical and economic viability of a mineral project that has advanced to a stage where a qualified person has determined (in the case of underground mining) a preferred mining method, or (in the case of surface mining) a pit configuration, and in all cases has determined an effective method of mineral processing and an effective plan to sell the product. A Pre-Feasibility Study includes a financial analysis based on reasonable assumptions, based on appropriate testing, about the modifying factors and the evaluation of any other relevant factors that are sufficient for a qualified person to determine if all or part of the Indicated and Measured Mineral Resources may be converted to mineral reserves at the time of reporting. The financial analysis must have the level of detail necessary to demonstrate, at the time of reporting, that extraction is economically viable. A Pre-Feasibility Study is less comprehensive and results in a lower confidence level than a feasibility study. A Pre-Feasibility study is more comprehensive and results in a higher confidence level than an Initial Assessment.

Initial Assessment
An Initial Assessment is a preliminary technical and economic study of the economic potential of all or parts of mineralization to support the disclosure of mineral resources. The Initial Assessment must be prepared by a qualified person and must include appropriate assessments of reasonably assumed technical and economic factors, together with any other relevant operational factors, that are necessary to demonstrate at the time of reporting that there are reasonable prospects for economic extraction. An Initial Assessment is required for disclosure of mineral resources but cannot be used as the basis for disclosure of mineral reserves. An Initial Assessment is preliminary in nature and includes Inferred Mineral Resources that are considered too speculative geologically to have the economic considerations applied that would enable them to be classified as mineral reserves. There is no certainty that the economic results of an initial assessment will be realized. The mineral resource estimates presented in the ABTC Tonopah Flats Initial Assessment were performed by third-party, qualified person RESPEC, LLC and were classified by geological and quantitative confidence in accordance with the Securities and Exchange Commission (SEC) Regulation S-K 1300.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are “forward-looking statements.” Although the American Battery Technology Company’s (the “Company”) management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. Forward looking statements include, among other things, statements concerning: offtake agreements with customers; the Company’s future sales of products to customers, including the amounts, timing, and types of products included within those sales; potential loans, grants, and debt financing arrangements, including due diligence, the amount and type of debt, its syndication, and the schedule for closing; the scale of the battery recycling operations; the anticipated production from the integrated pilot facility; the scale, construction, and operation of the battery recycling operations, integrated pilot facility, Tonopah Flats Lithium Project, and commercial lithium mine and refinery; and the costs, schedules, production and economic projections associated with the foregoing. These forward-looking statements involve a number of risks and uncertainties, which could cause the Company’s future results to differ materially from those anticipated. Potential risks and uncertainties include, among others, risks and uncertainties related to the Company’s ability to continue as a going concern; interpretations or reinterpretations of geologic information, unfavorable exploration results, inability to obtain permits required for future exploration, development or production, general economic conditions and conditions affecting the industries in which the Company operates; the uncertainty of regulatory requirements and approvals; fluctuating mineral and commodity prices, final investment approval and the ability to obtain necessary financing on acceptable terms or at all. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended June 30, 2026. The Company assumes no obligation to update any of the information contained or referenced in this press release.

American Battery Technology Company 
Media Contact: 
Tiffiany Moehring 
tmoehring@batterymetals.com 
720-254-1556 

AMERICAN BATTERY TECHNOLOGY COMPANY Consolidated Statements of Operations
		Three months ended September 30, 2026				Three months ended September 30, 2025
Revenue		$	1,713,289			$	937,589
Cost of goods sold			5,355,954				4,454,231
Gross profit (loss)			(3,642,665	)			(3,516,642	)
Expenses:
General and administrative		$	7,284,644			$	3,628,127
Research and development			3,630,975				2,697,639
Exploration costs			437,423				290,951
Total operating expenses			11,353,042				6,616,717
Net loss before other income (expense)			(14,995,707	)			(10,133,359	)
Other income (expense)
Interest income (expense)			371,830				(6,469	)
Amortization and accretion of financing costs			–				(307,428	)
Other income (expense), net			(101	)			147,690
Total other income (expense)			371,729				(166,207	)
Net loss		$	(14,623,978	)		$	(10,299,566	)
Net loss per share, basic and diluted		$	(0.10	)		$	(0.09	)
Weighted average shares outstanding			142,101,524				112,240,128

AMERICAN BATTERY TECHNOLOGY COMPANY Consolidated Balance Sheets
		September 30, 2026				June 30, 2026
ASSETS
Cash and cash equivalents		$	43,261,719			$	49,519,474
Accounts receivable			3,036,105				6,952,929
Inventory (Note 4)			2,823,375				584,763
Grants receivable (Note 5)			31,164				217,771
Other receivable			–				561,940
Prepaid expenses and other			1,939,293				2,296,785
Restricted cash			100,000				800,000
Total current assets			51,191,656				60,933,662
Property and equipment, net (Note 6)			57,672,990				57,294,191
Mining properties (Note 7)			10,019,655				9,819,655
Intangible assets (Note 8)			4,618,592				4,618,592
Right-of-use asset (Note 10)			142,972				173,609
Total assets		$	123,645,865			$	132,839,709
LIABILITIES & STOCKHOLDERS’ EQUITY
Accounts payable and accrued liabilities (Note 9)		$	6,075,318			$	6,263,435
Operating lease liability (Note 10)			135,339				131,287
Total current liabilities			6,210,657				6,394,722
Operating lease liability, long-term			23,785				58,876
Total liabilities			6,234,442				6,453,598
Total stockholders’ equity			117,411,423				126,386,111
Total liabilities and stockholders’ equity		$	123,645,865			$	132,839,709

Executes term sheet with the U.S. Army for a heavy rare earth processing facility at Tooele Army Depot; advances SRC metallization and Rare Earth Processing Facility programs; outlines steps toward targeted initial U.S. magnet production by 2030; $116.2 million of cash at quarter-end

• Subsequent to quarter-end, executed a non-binding term sheet with the Department of the Army setting out the principal terms for negotiating a definitive Enhanced Use Lease for a heavy rare earth processing facility on approximately 200 acres at Tooele Army Depot, Utah
• Advanced the Heavy Rare Earth Metallization Facility, targeting commissioning in the first quarter of 2028 with targeted capacity of approximately 50 tonnes of annual dysprosium and terbium oxide
• Targeting North American rare earth metal production, with access to NdPr metallization capability at SRC expected beginning in the first quarter of 2027 and dysprosium and terbium metal output from the Company’s metallization facility expected in the first half of 2028, addressing the limited North American production of rare earth metals
• Provided additional detail on the Company’s mine-to-magnet strategy and the steps toward a targeted initial U.S.-based production of approximately 3,000 tonnes per year of sintered NdFeB magnets no later than 2030
• Plans to dedicate approximately $10 million through 2027 to research and development, piloting, and product qualification with the Euclid facility at the center of these activities
• Ended the quarter with $116.2 million of cash and a virtually debt-free balance sheet, with spending sequenced to project milestones

EUCLID, Ohio, Nov. 13, 2026 (GLOBE NEWSWIRE) — REalloys Inc. (Nasdaq: ALOY) (the “Company” or “REalloys”), today reported results for the third quarter ended September 30, 2026.

Net revenues were $0.4 million, compared with $0.2 million in the third quarter of 2025, and the Company reported a net loss of $30.5 million, or $0.44 per diluted share, compared with a net loss of $25.6 million, or $0.58 per diluted share, in the prior-year quarter.

The net loss was driven primarily by $25.3 million of non-cash stock-based compensation associated with director, officer and consultant equity awards, primarily granted in connection with the Company’s February 2026 transition to a Nasdaq-listed public company.

“This quarter we moved further from planning into execution. The term sheet with the U.S. Army at Tooele, the initial funding of expanded NdPr metallization capacity at SRC and continued progress on our heavy rare earth metallization facility advance our path toward North American rare earth metal production, which we are targeting to begin in 2027. With Department of War sourcing restrictions taking effect on January 1, 2027, we believe demand for secure, non-Chinese supplies of NdPr, dysprosium and terbium will continue to grow. We are managing our capital with discipline, sequencing spending to technical and commercial milestones, and we expect to fund our committed programs from existing cash as we take the next steps toward our targeted initial U.S. magnet production by 2030.”

— Leonard Sternheim, Chief Executive Officer of REalloys

Third Quarter Financial Highlights

• The Company’s cash balance as of September 30, 2026 was approximately $116.2 million
• Deployed $16.5 million to SRC programs during the first nine months of 2026, including $11.6 million toward the Heavy Rare Earth Metallization Facility, $3.7 million toward the Rare Earth Processing Facility upgrade and $1.2 million toward process development, in line with the Company’s capital plans
• Maintained a strong, virtually debt-free balance sheet, against $197.4 million of assets and $123.4 million of working capital

Euclid facility sales drove revenue growth with approximately 36% gross margin. General and administrative expense for the quarter included $25.3 million of non-cash stock-based compensation; excluding it, general and administrative expense was approximately $4.9 million (a non-GAAP measure; see “Non-GAAP Financial Measures” below).

For the nine months ended September 30, 2026, net revenues were $1.9 million, compared with $0.6 million in the prior-year period, and net loss was $174.1 million, or $2.83 per diluted share, compared with a net loss of $29.5 million, or $0.75 per diluted share, in the prior-year period. The nine-month net loss included $158.2 million of non-cash charges, principally $139.2 million of stock-based compensation, $9.2 million of preferred share accretion, a $6.4 million impairment related to assets acquired through the Blackboxstocks merger and a $3.4 million change in the fair value of settled derivatives.

Strategic Projects Update and Outlook

Heavy Rare Earth Metallization Facility. The Company is advancing engineering and equipment procurement for its planned Heavy Rare Earth Metallization Facility, which is targeted for commissioning in the first quarter of 2028 and initial operations in the first half of 2028, with an estimated annual processing capacity of approximately 50 tonnes of combined dysprosium and terbium oxide feedstock.

SRC Rare Earth Processing Facility Upgrade. REalloys has initiated its planned funding under the upgrade agreement with SRC. Initial funding has been directed to completing NdPr metallization units, representing approximately one-third of the estimated total upgrade budget, which are expected to give the Company access to North American NdPr metal production capability beginning in the first quarter of 2027. Release of the remaining funds, which relate primarily to the separation system upgrade, has been deferred to 2027 while near-term activity at SRC focuses on commissioning and operating the existing facility. The Company does not expect the deferral to affect its supply of critical materials from SRC. The upgrade is intended to increase annual production capacity up to approximately 525 tonnes of NdPr metal, 30 tonnes of dysprosium oxide and 15 tonnes of terbium oxide, and REalloys has secured supply rights to approximately 80% of the facility’s output and has a Right of First Refusal on the uncommitted remaining output.

Together with SRC, the Company is advancing processing and separation trials using recycled mixed rare earth oxide and mixed rare earth carbonate feedstock through the first half of 2027. These trials were previously expected to be completed in 2026; the timing has shifted primarily due to feedstock alignment and procurement lead times, and the Company does not expect the change to affect its broader strategic execution plan. The Company expects initial separated oxide production from the SRC facility in the second half of 2027 and commercial intake of NdPr metal and dysprosium and terbium oxides from SRC to commence in the third quarter of 2027.

Integrated U.S. Separation, Metallization and Magnet Platform. REalloys has provided additional detail on the next stage of its mine-to-magnet strategy: a stage-gated, U.S.-based platform covering rare earth separation, metallization and sintered NdFeB magnet manufacturing, primarily serving U.S. defense, automotive and advanced industrial customers. The platform targets initial production of approximately 3,000 tonnes per year of magnets no later than 2030, supported by targeted annual production of up to 1,250 tonnes of NdPr metal, 60 tonnes of dysprosium metal and 25 tonnes of terbium metal. These capacity figures are design targets, not commitments, forecasts or guidance. is evaluating Tooele Army Depot as a potential site for these facilities; because the term sheet contemplates a facility initially focused on dysprosium and terbium and a definitive lease may not accommodate all of the planned facilities, the Company is also evaluating alternative sites. The location, timing and capital requirements of these facilities have not yet been determined, and their development is expected to require significant additional financing. The Company plans to spend approximately $10 million through 2027 on research and development, piloting and product qualification, centered at the Euclid facility. The facility, product qualification, and cost estimation for separation, metallization, and magnet facilities, centered at the Euclid facility.is being assessed as a potential location for a future pilot-scale magnet manufacturing facility.

Capital Resources and Liquidity. As of September 30, 2026, remaining commitments under the SRC development agreements were approximately $56.0 million and are expected to be incurred through 2028 to bring the Company’s processing and metallization projects to commissioning. The Company expects to fund these requirements, its planned research and development, piloting and product qualification spending and general corporate costs from existing cash, without reliance on any specific future financing transaction. The Company is taking a disciplined, stage-gated approach to capital allocation: spending is sequenced to technical and commercial milestones, and commitments to larger-scale production facilities will follow the results of the Company’s research and development, piloting and product qualification work.

Recent Developments

U.S. Army Term Sheet at Tooele Army Depot. On November 3, 2026, REalloys announced that it and the Department of the Army had executed a non-binding term sheet setting out the principal terms for negotiating a definitive Enhanced Use Lease for a facility to process and refine critical minerals, including dysprosium and terbium, on approximately 200 acres at Tooele Army Depot in Utah. The indicative terms include an initial 50-year term with one 25-year renewal subject to Army consent, fair market value base rent plus participation rent (the rate and basis of which have not been agreed), and a right of first offer to the Army on facility output, without any obligation to purchase. The term sheet is non-binding, other than certain customary provisions, and execution of a definitive lease is subject to conditions including agreement on rent, Army acceptance of the Company’s development plan, completion of environmental reviews, adequate permit capacity, project financing, approval by the Company’s Board of Directors and required Army determinations and Congressional notifications.

About REalloys Inc.

REalloys Inc. (NASDAQ: ALOY) is a U.S.-based rare earth materials company executing a mine-to-magnet strategy across upstream feedstock, midstream separation and metallization, and downstream magnet manufacturing. REalloys is focused on delivering qualified, allied-nation rare earth metals and alloys, including dysprosium, terbium, and neodymium, to the U.S. Department of War, the U.S. Department of Energy, NASA, the U.S. Defense Industrial Base, and the broader U.S. Organic Industrial Base.

For more information, please visit www.REalloys.com or email InvestInAmerica@REalloys.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding: the planned Heavy Rare Earth Metallization Facility and its targeted capacity, commissioning and initial operations; the SRC Rare Earth Processing Facility upgrade, including the timing of funding, NdPr metallization capability and the separation system upgrade; the timing of separation trials, separated oxide production and commercial intake of rare earth materials from SRC; the scope, capacity targets, siting, cost, financing and timing of the Company’s planned U.S. separation, metallization and magnet platform, including targeted magnet production by 2030; planned research and development, piloting and product qualification spending; the role of the Euclid facility; the negotiation, terms, conditions and potential execution of an Enhanced Use Lease at Tooele Army Depot; the Company’s planned expenditures and the sufficiency of its capital resources; and expected demand for non-Chinese rare earth materials, including as a result of U.S. Department of War procurement restrictions.

These forward-looking statements are based on the Company’s current expectations and involve significant risks and uncertainties that could cause actual results to differ materially, including those described under “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC. The Company undertakes no obligation to update these statements except as required by law.

Non-GAAP Financial Measures

This press release includes “Adjusted General and Administrative Expense,” which excludes non-cash stock-based compensation expense from GAAP general and administrative expense. The Company presents this measure because management believes it provides useful information about the Company’s cash-based operating cost structure, particularly given the significant non-cash stock-based compensation charges recognized in connection with the Company’s February 2026 reverse recapitalization and public listing. This non-GAAP measure should not be considered in isolation or as a substitute for the most directly comparable GAAP measure and should be read in conjunction with the Company’s condensed consolidated financial statements prepared in accordance with GAAP. The following reconciles GAAP general and administrative expense to Adjusted General and Administrative Expense (in thousands):

Reconciliation of Adjusted General and Administrative Expense
(In thousands, unaudited)

		Three Months Ended Sep 30, 2026			Nine Months Ended Sep 30, 2026
General and administrative expense (GAAP)	$	30,263		$	151,719
Less: non-cash stock-based compensation		(25,319	)		(139,179	)
Adjusted General and Administrative Expense (non-GAAP)	$	4,944		$	12,540

Financial Statements

Condensed Consolidated Statements of Operations (Unaudited)
(In thousands, except share and per share data)

		3M Sep 30, 2026			3M Sep 30, 2025			9M Sep 30, 2026			9M Sep 30, 2025
Net revenues	$	413		$	186		$	1,923		$	626
Cost of sales		263			168			890			387
Software development costs		–			–			68			–
General and administrative		30,263			27,289			151,719			29,213
Advertising and marketing		486			–			4,337			–
Depreciation and amortization		185			68			177			135
Total operating expenses		31,197			27,525			157,191			29,735
Loss from operations		(30,784	)		(27,339	)		(155,268	)		(29,109	)
Interest expense		7			94			29			278
Change in fair value of contingent consideration		–			832			3,439			(480	)
Deferred cash consideration late payment penalties		–			(2,677	)		–			624
Impairment expense		–			–			6,394			–
Accretion of discount on issuance of Series C Preferred Stock		–			–			9,220			–
Other (income) expense, net		(252	)		–			(275	)		–
Total other (income) expense		(245	)		(1,751	)		18,807			422
Net loss	$	(30,539	)	$	(25,588	)	$	(174,075	)	$	(29,531	)
Basic and diluted net loss per share	$	(0.44	)	$	(0.58	)	$	(2.83	)	$	(0.75	)
Weighted-average shares outstanding, basic and diluted		69,050,348			44,490,419			61,527,891			39,501,673

Condensed Consolidated Balance Sheets (Selected Data)
(In thousands)

		September 30, 2026 (unaudited)			December 31, 2025 (audited)
Cash	$	116,182		$	2,824
Total current assets		129,055			38,541
Total assets		197,373			93,389
Total current liabilities		5,611			7,154
Total liabilities		19,740			56,049
Total stockholders’ equity		177,633			35,834
Working capital		123,444			31,387
Accumulated deficit		(255,200	)		(81,125	)

Condensed Consolidated Statements of Cash Flows (Selected Data)
(In thousands, unaudited)

		Nine Months Ended Sep 30, 2026			Nine Months Ended Sep 30, 2025
Net cash used in operating activities	$	(23,431	)	$	(2,631	)
Net cash used in investing activities		(8,528	)		(53	)
Net cash provided by financing activities		145,317			2,844
Net change in cash	$	113,358		$	160

• New INTEGUMENT-INFANT trial results demonstrate improvements in itch, reductions in symptoms, and improvements in quality of life for infants with atopic dermatitis and their families
• Findings further support investigational ZORYVE cream 0.05% to help address unmet needs in infants aged 3 to <24 months
• 60% of children develop atopic dermatitis symptoms within their first year of life

WESTLAKE VILLAGE, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new caregiver-reported outcomes data from the INTEGUMENT-INFANT trial supporting ZORYVE^® (roflumilast) cream 0.05% in the treatment of infants with mild to moderate atopic dermatitis ages 3-24 months presented at the American College of Allergy, Asthma & Immunology’s (ACAAI) Annual Scientific Meeting, taking place Nov. 12-16 in Phoenix, Arizona.

“Managing atopic dermatitis in infants can be particularly challenging, especially given the lifelong, chronic nature of the disease and the fact that the skin barrier and immune system are still developing. Today, there are very limited approved treatment options for infants, especially steroid-free options, leaving healthcare providers and caregivers with too few options,” said Mark Boguniewicz, MD, professor, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine. “These new findings showed that alongside having a generally safe and well-tolerated profile, ZORYVE demonstrated improvements in the signs and symptoms of atopic dermatitis, as well as quality of life measurements, as reported by caregivers. These results underscore the importance of expanding treatment options to address the unique needs of this vulnerable population.”

Atopic dermatitis is the most common form of eczema with 60% of children developing symptoms within their first year of life. The combination of itching and associated sleep disturbance for infants with atopic dermatitis, as well as the financial and emotional stress of treatment experienced by caregivers, results in significant disease burden.

“These new caregiver-reported outcomes showing improvement in both symptoms and quality of life measures add to the growing body of clinical evidence supporting the potential of ZORYVE cream 0.05% to address a significant unmet need for infants with atopic dermatitis and their families,” said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis. “Together with previously reported results, these findings reinforce the potential of ZORYVE to provide a well-tolerated, steroid-free treatment option for managing the burdensome symptoms of atopic dermatitis that can begin in infancy. With our supplemental New Drug Application currently under FDA review, we look forward to the possibility of bringing this important new treatment option to infants as young as 3 months of age, if approved.”

A total of 101 infants were enrolled in the INTEGUMENT-INFANT trial evaluating ZORYVE cream 0.05%. Caregiver-reported outcomes demonstrated improvements in itch, atopic dermatitis symptoms, and quality of life for infants and their families.

Key findings include:

• Favorable tolerability: ZORYVE cream 0.05% was well tolerated, with no serious adverse events (SAEs) or severe treatment-emergent adverse events (TEAEs) reported (n=101). At least 97.9% of infants had no evidence of investigator-rated application-site irritation across assessment timepoints.
• Improvements in itch: Caregivers reported improvements in itch as early as 10 minutes after the first application, with 46.6% of infants achieving a ≥25% improvement in itch (Dynamic Pruritus Score–25; n=88), increasing to 66.7% of infants at 4 hours (n=87). Additionally, 10.4% of infants achieved WSI-NRS success at 24 hours (n=77), increasing to 72.7% of infants at the last assessment (n=77).
• Improvements in atopic dermatitis symptoms: Caregivers reported reductions in the frequency of symptoms such as bleeding, cracking, dryness, flaking, itching, weeping, and sleep loss, as measured by the Patient-Oriented Eczema Measure (POEM), which assesses the frequency of eczema symptoms over the previous week, with scores ranging from 0 to 28 (higher scores indicating greater disease severity). Mean POEM scores decreased from 14.5 at baseline (moderate severity) to 7.9 at Week 2 (n=100) and 6.5 at Week 4 (n=96), reflecting a shift from moderate to mild disease severity.
• Improvements in infant quality of life and family impact: Caregivers reported improvements in infant quality of life, as measured by the Infants’ Dermatitis Quality of Life Index (IDQoL), and improvements in family quality of life, as measured by the Dermatitis Family Impact (DFI) questionnaire. Improvements with investigational ZORYVE cream 0.05% were reported across factors including daily activities, sleep, emotional well-being, family activities, and relationships.

ePoster presentation details are as follows:

• R378: Caregiver-Reported Outcomes With Roflumilast Cream in Infants Aged 3 to Less Than 24 Months: INTEGUMENT-INFANT
• Date & Time: Friday, Nov. 13 at 3:30 p.m. MST
• Location: North Halls (4-6) Lower Level, Monitor 25

ZORYVE cream 0.05% is approved in the United States for the topical treatment of mild to moderate atopic dermatitis in children aged 2-5 years. A supplemental New Drug Application (sNDA) for ZORYVE cream 0.05% to expand the indication for the topical treatment of mild to moderate atopic dermatitis to include infants aged 3 to 24 months is under review, with a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027.

About Atopic Dermatitis
Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the United States. Atopic dermatitis is a chronic, relapsing, and genetically predisposed inflammatory skin disease. The disease typically appears as a red, intensely itchy rash that can occur anywhere on the body. Younger children may have especially widespread atopic dermatitis, including on the face and neck.

Atopic dermatitis is often initially diagnosed during childhood with approximately 90% of people with atopic dermatitis developing symptoms by age 5 and up to 60% of children developing symptoms within their first year. Pediatric atopic dermatitis can negatively impact the entire family by significantly disrupting sleep, increasing the risk of skin infections, and leading to developmental and emotional strain for both the child and caregivers.

About ZORYVE^® (roflumilast)
ZORYVE is the number one prescribed branded topical therapy across three major inflammatory dermatoses combined — atopic dermatitis (eczema), seborrheic dermatitis, and plaque psoriasis. ZORYVE is a topical formulation of roflumilast, an advanced targeted topical phosphodiesterase type 4 (PDE4) inhibitor. Inhibiting PDE4, an intracellular enzyme that is an established target in dermatology, decreases the production of pro-inflammatory mediators. This decreases inflammation in the skin and balances the skin’s immune system.

Demonstrating both clinical impact and broad industry recognition, ZORYVE has been honored with multiple prestigious awards, including three from major beauty magazines: Allure’s “2025 Best of Beauty Breakthrough Award,” Glamour’s 2024 Beauty and Wellness Award for “Best Eczema Product,” and most recently, Marie Claire’s “2026 Best Prescription Skin Solution” Award.

In addition, the National Psoriasis Foundation honored ZORYVE with its Seal of Recognition and the American Academy of Dermatology (AAD) issued a strong recommendation for the use of ZORYVE cream 0.15% in adults with mild to moderate atopic dermatitis and ZORYVE cream 0.05% for children aged 2-5 years, as well as a strong recommendation for ZORYVE cream 0.15% for children aged 6 years and older with mild to moderate atopic dermatitis in its first-ever pediatric atopic dermatitis guidelines.

INDICATIONS
ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age.

ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 2 years of age and older. 

ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older. 

IMPORTANT SAFETY INFORMATION
ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.05% for pediatric patients with atopic dermatitis 2 to 5 years of age were upper respiratory tract infection (4.1%), diarrhea (2.5%), vomiting (2.1%), rhinitis (1.6%), conjunctivitis (1.4%), and headache (1.1%).

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.15% for patients with atopic dermatitis 6 years of age or older were headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.3% for plaque psoriasis were diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).

The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for plaque psoriasis were headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%).

The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis were nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).

Please see full Prescribing Information for ZORYVE foam and full Prescribing Information for ZORYVE cream. 

About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company delivering meaningful innovation to address the needs of individuals living with chronic inflammatory skin diseases. Over the past decade, Arcutis has successfully developed a robust portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases, driven by a commitment to solving the most persistent patient challenges in dermatology. Arcutis’ unique dermatology development platform, built on established scientific pathways and coupled with deep clinical dermatology and commercial expertise, enables us to efficiently develop, scale, and deliver our differentiated therapies while advancing a growing pipeline across a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X. 

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential FDA approval of ZORYVE cream 0.05% for the treatment of infants with mild to moderate atopic dermatitis ages 3-24 months, its potential to advance the standard of care in AD, and clinical trial results translating into real world results, including among others, tolerability, itch and quality of life. These statements are subject to substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com

Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com

Proposed EGM resolutions allow previously announced share cancellations to be finalised to reduce public float and increase Net Asset Value Per Share (NAVPS), while providing flexibility to maintain listing compliance and broaden institutional market access.

SINGAPORE, Nov. 13, 2026 (GLOBE NEWSWIRE) — Genius Group Limited (NYSE American: GNS) (“Genius Group”, “GNS” or the “Company”), a leading AI-powered education group, today announced that its Board of Directors has called an Extraordinary General Meeting of shareholders (the “EGM”) to approve the cancellation of up to 27,387,374 Class A ordinary shares to advance the company’s commitment to reducing its public float, and precautionary authority for a further share consolidation, if required, to maintain exchange compliance and support a more institutional-grade share structure. The EGM will be held on December 29, 2026 at 3:00 p.m. (Singapore time) at The Great Room, Stateroom Meeting Room, 3 Temasek Avenue, Level 18, Centennial Tower, Singapore 039190.

As part of the broader share retirement program announced in April 2026, the Company completed buybacks of approximately 12.6 million shares in June 2026. The proposed share cancellations now relate to 20,000,000 ERL-related shares, comprising 14,546,057 shares surrendered by Entrepreneur Resorts Ltd (“ERL”) and 5,453,943 shares held in the Company’s treasury. Further to the Company’s June 17, 2026 announcement regarding the return and cancellation of these shares, shareholder approval is now being sought under Singapore law to complete the legal cancellation process.

Roger James Hamilton, Founder and CEO of Genius Group, commented, “These share cancellations are an important step in our commitment to reducing the outstanding share count and strengthening the capital structure for all shareholders. Together with our recent buyback, these actions are designed to create a cleaner capital structure. The share consolidation taking effect on November 20 is required to maintain NYSE American listing compliance, while the precautionary authority being sought at the EGM would give the Board flexibility, if needed, to maintain compliance with applicable exchange requirements and support a more institutional-grade share structure as we continue to grow the business, advance our proposed ASX dual listing and attract investors wishing to support our Genius City and GENIUSpark community-first data center model in Australia and South East Asia.”

Genius Group has been restructuring the company to increase its Net Asset Value Per Share (NAVPS), closing or restructuring loss-making divisions, repaying 99% of all third-party debt, and increasing net assets to US$106 million. The Company’s operating units delivered US$6.7 million in combined net profit from operations on 112% revenue growth year-on-year in the first nine months of 2026, and recently reported NAVPS of $0.61 per share.

The announcement of the EGM follows the Company’s 1-for-10 share consolidation expected to become effective on November 20, 2026, which will reduce the number of shares outstanding to one-tenth of the current amount and increase NAVPS tenfold, without changing the Company’s aggregate net assets or shareholders’ proportionate ownership. The share cancellation resolutions, if passed, would further reduce the number of shares outstanding and increase NAVPS, assuming net assets remain unchanged.

The Board has fixed November 24, 2026 as the record date for determining shareholders entitled to receive notice of, and to vote at, the EGM. The Company has notified NYSE American of the record date in accordance with its requirements.

Resolutions to be voted on at the EGM

Special Resolution 1: Cancellation of 20.0 million ERL shares: approval under Section 76D of the Singapore Companies Act 1967 for the selective off-market acquisition and cancellation of 14,546,057 Class A ordinary shares surrendered by Entrepreneur Resorts Ltd (“ERL”) for nil consideration together with the cancellation of 5,453,943 Class A ordinary shares, collectively totalling 20,000,000 shares (on a pre-consolidation basis, or approximately 2,000,000 shares following the 1-for-10 share consolidation), ERL is voluntarily surrendering these shares under the Share Surrender and Cancellation Agreement dated June 16, 2026. directly reducing the Company’s outstanding share count.

Special Resolution 2: Cancellation of up to 7.4 million LZG shares: conditional approval under Section 76D for the acquisition and cancellation of up to 7,387,374 Class A ordinary shares (on a pre-consolidation basis, or approximately 738,737 shares following the 1-for-10 share consolidation) held by LZG International, Inc. (“LZG”), which the Company is entitled to have returned under a final ICC arbitration award dated April 20, 2026. The shares would be cancelled only once they are transferred or surrendered to the Company following a court order, a transfer by LZG’s liquidator, or a voluntary return by LZG.

Ordinary Resolution 3: Precautionary consolidation authority: authority for the Board, at its discretion, to implement a further share consolidation within a range of 1-for-3 to 1-for-19, in one or two steps, at any time within 18 months of the EGM. This authority is precautionary, to give the Board flexibility to maintain compliance with NYSE American continued listing requirements and the requirements of any other exchange on which the Company proposes to list, including the Australian Securities Exchange. No further consolidation is currently planned for implementation.

Special Resolutions 1 and 2 require the approval of at least 75% of the votes cast, and Ordinary Resolution 3 requires a simple majority. ERL and LZG, and their respective associates, will abstain from voting on the resolution relating to them.

Notice of EGM and voting

The notice of EGM, including the full text of the resolutions and explanatory notes, and the proxy form will be furnished on Form 6-K, published on the Company’s website at https://ir.geniusgroup.net/ and distributed to shareholders in due course. Shareholders who hold their shares through a bank, broker or other nominee will receive voting instructions from their intermediary. Completed proxy forms must be received at least 72 hours before the EGM.

About Genius Group

Genius Group (NYSE: GNS) is a global education group delivering AI powered, education and acceleration solutions for the future of work. Genius Group serves 6 million users in over 100 countries through its Genius City model and online digital marketplace of AI training, AI tools and AI talent. It provides personalized, entrepreneurial AI pathways combining human talent with AI skills and AI solutions at the individual, enterprise and government level. To learn more, please visit geniusgroup.ai.

Investor Notice

Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks, uncertainties and forward-looking statements described in our most recent Annual Report on Form 20-F, as amended for the fiscal year ended December 31, 2025, filed with the SEC on March 9, 2026. If any of these risks were to occur, our business, financial condition or results of operations would likely suffer. In that event, the value of our securities could decline, and you could lose part or all of your investment. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. In addition, our past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results in the future. See “Forward-Looking Statements” below.

Forward-Looking Statements

Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by the use of words such as “may,” “will”, “plan,” “should,” “expect,” “anticipate,” “estimate,” “continue,” or comparable terminology. Such forward-looking statements are inherently subject to certain risks, trends and uncertainties, many of which the Company cannot predict with accuracy and some of which the Company might not even anticipate and involve factors that may cause actual results to differ materially from those projected or suggested. Readers are cautioned not to place undue reliance on these forward-looking statements and are advised to consider the factors listed above together with the additional factors under the heading “Risk Factors” in the Company’s Annual Reports on Form 20-F, as may be supplemented or amended by the Company’s Reports of a Foreign Private Issuer on Form 6-K. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise. No information in this press release should be construed as any indication whatsoever of the Company’s future revenues, results of operations, or stock price.

Contacts

For enquiries, contact investor@geniusgroup.ai

CHAD, the Nasdaq-listed daily dividend preferred stock, reached its $10.00 stated amount in 48 days; tokenized CHADx has traded more than $2.8 million onchain since November 10, more than 3x that on Nasdaq, following its launch with xStocks and new fixed and variable rate markets on Exponent

BOCA RATON, FL, Nov. 13, 2026 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced that its Variable Rate Series C Perpetual Preferred Stock (Nasdaq: CHAD) has completed 30 consecutive business-day dividend payments, from its first regular dividend payment on October 1, 2026 through [TK: November 13, 2026].

CHAD, a daily dividend preferred stock and SOL-powered digital credit instrument, currently pays a variable annual dividend rate of 14.00%, or $1.40 per share per year on its $10.00 stated amount ($0.00614 per share each business day in the November 2026 dividend period). Dividends are cumulative and payable each business day when, as, and if declared by the Company’s Board of Directors. Dividends are not guaranteed, and the dividend rate is subject to change.

“Thirty consecutive dividend payments is exactly what we built CHAD to do: pay holders every business day, from day one,” said Joseph Onorati, Chief Executive Officer of DeFi Development Corp. “Together with CHAD’s run to par and its arrival onchain as CHADx, this is further evidence that SOL-powered digital credit is working as intended.”

48 Days to Par
CHAD began trading on Nasdaq on September 8, 2026, after pricing its initial public offering at $8.00 per share. It closed at its $10.00 stated amount (“par”) on October 26, 2026, 48 calendar days after its debut, making CHAD the fastest progression to par among digital credit securities to date.

CHADx Brings CHAD Onchain
On November 11, 2026, the Company announced that CHAD has been tokenized in partnership with xStocks. CHADx is a 1:1 tokenized version of CHAD, backed by CHAD shares held in custody and live on Solana and nine other major blockchains. CHADx is offered through xStocks, is not issued by DeFi Development Corp., and does not confer ownership of CHAD shares or shareholder rights. CHAD’s daily dividends are designed to be reflected in CHADx holders’ token balances each trading day.

Since November 10, 2026, CHADx has traded more than $2.8 million onchain, according to Solscan. By comparison, CHAD collectively traded approximately $0.74 million on November 10 and 11, according to Nasdaq.

Fixed and Variable Rates on Exponent
CHADx is also availableon Exponent, a Solana decentralized finance (DeFi) protocol that splits yield into fixed and variable rates. Through Exponent’s CHADx market, which matures February 26, 2027, eligible users can:

• Lock in a fixed rate with PT-CHADx (principal token).
• Take leveraged variable-yield exposure with YT-CHADx (yield token), which also earns 2x xPoints, Exponent’s rewards program.
• Provide liquidity to earn swap fees, yield from the underlying CHADx and PT-CHADx, and 1x xPoints.

Note: CHADx, xStocks and Exponent are not available in the United States or to U.S. persons. Geographic restrictions apply.  Nothing in this press release is an offer to sell or a solicitation of an offer to buy CHADx, PT-CHADx, YT-CHADx or any other product of xStocks or Exponent. Information in this press release about CHADx, xStocks and Exponent has been provided by those parties or derived from public sources and has not been independently verified by the Company. The Company does not control xStocks or Exponent and is not responsible for them or their products.

Frequently Asked Questions

What is CHAD?
CHAD (Nasdaq: CHAD) is DeFi Development Corp.’s Variable Rate Series C Perpetual Preferred Stock, a daily dividend preferred stock bought and sold in a brokerage account like other Nasdaq-listed stocks. It has a $10.00 stated amount and no maturity date. CHAD is not a crypto token and does not represent an ownership interest in SOL or any other assets held by the Company.

How do CHAD’s daily dividends work?
CHAD is designed to pay a cash dividend every business day, when, as, and if declared, to holders of record at the close of the prior business day. The current variable annual rate is 14.00% of the $10.00 stated amount and may change, subject to the limitations in the certificate of designation governing CHAD. Unpaid dividends accumulate and dividends are not guaranteed.

What is CHADx?
CHADx is a 1:1 tokenized version of CHAD offered by xStocks on Solana and nine other blockchains. It is not issued by DeFi Development Corp. and is not available in the United States or to U.S. persons.

How can CHADx be used in DeFi?
Where permitted, CHADx can be held in a wallet, traded onchain, and used on Exponent to lock in a fixed rate (PT-CHADx), take variable-yield exposure (YT-CHADx), or provide liquidity.

About DeFi Development Corp.
DeFi Development Corp. (Nasdaq: DFDV) has adopted a treasury policy under which the principal holding in its treasury reserve is allocated to SOL. Through this strategy, the Company provides investors with economic exposure to SOL, while also actively participating in the growth of the Solana ecosystem. In addition to holding and staking SOL, DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake. The Company is also engaged across decentralized finance (DeFi) opportunities and continues to explore innovative ways to support and benefit from Solana’s expanding application layer.

The Company is also an AI-powered online platform that connects the commercial real estate industry by providing value-add services and software subscriptions to multifamily and commercial property professionals, as the Company connects the increasingly complex ecosystem that stakeholders have to manage. The Company’s data and software offerings are generally offered on a subscription basis as software as a service.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include, without limitation, statements regarding the Company’s treasury strategy, the payment, amount and frequency of future dividends on CHAD, the dividend rate on CHAD, the trading price and liquidity of CHAD and the operation of CHADx and of third-party products that reference CHADx. Words such as “believe”, “designed to”, “expect”, “intend”, “may”, “seek”, “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including: whether the Company’s Board of Directors declares future dividends on CHAD and whether the Company has funds legally available to pay them; changes to the dividend rate on CHAD; fluctuations in the price of SOL and in the trading price of CHAD; the Company’s ability to generate staking and other income; the operation, availability and regulatory status of xStocks, Exponent and other third-party platforms, over which the Company has no control; changes in laws and regulations applicable to digital assets, tokenized securities and decentralized finance; and the other risks described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, its subsequent Quarterly Reports on Form 10-Q and the prospectus supplement relating to CHAD, each filed with the Securities and Exchange Commission. Past dividend payments and trading performance are not indicative of future results. Forward-looking statements speak only as of the date of this press release and, except as required by law, the Company undertakes no obligation to update them.

DeFi Development Corp. has filed a registration statement (including a prospectus) with the Securities and Exchange Commission (SEC) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents DeFi Development Corp. has filed with the SEC for more complete information about DeFi Development Corp. and this offering.  You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov.  Alternatively, DeFi Development Corp., any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling toll-free 1-212-293-9090. The documents are also available at defidevcorp.com/disclaimer.

Investor Contact:
ir@defidevcorp.com

Media Contact:
press@defidevcorp.com

HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) — KOIL Energy Solutions, Inc. (OTCQB: KLNG), a specialist in deepwater energy production and distribution equipment and services, today announced its third quarter 2026 results.

• Record revenue of $10.3 million, 62% year-over-year increase compared to third quarter of 2025
• Fifth quarter of sequential quarterly double-digit revenue growth
• Adjusted EBITDA of $837,000 or 8% of revenue
• Awarded first significant contract in Brazil
• Raised $5.6 Million in Equity Capital to finance rental equipment

“The KOIL team continues to raise the bar, delivering record revenue quarter after quarter while surpassing one million work hours without a recordable incident,” said Erik Wiik, President and Chief Executive Officer of KOIL Energy. “Achieving profitable growth alongside this extraordinary safety milestone is truly remarkable. We also deeply appreciate the confidence our investors have placed in KOIL by providing the equity capital to further expand our service capacity. Their support has strengthened our position to capitalize on the opportunities in a robust subsea market.”

Third Quarter 2026 Financial Results:

For the three months ending September 30, 2026, KOIL Energy generated revenues of $10.3 million, 62% higher than the third quarter of 2025, and a 13% increase sequentially. The KOIL team demonstrated impressive flexibility and responsiveness in meeting increased customer demand for subsea services, with service contracts accounting for approximately 70% of revenue.

Gross profit for the quarter totaled $2.8 million, or 27% of revenues, compared to $2.1 million, or 32% of revenues, during the third quarter of 2025. Selling, general, and administrative expenses during the quarter equaled $2.3 million compared to $2.5 million year over year. Adjusted EBITDA equaled 8% of revenue, representing an increase of $1.1 million compared with the third quarter of 2025.

Corporate Updates:

During the quarter it was announced that KOIL secured a significant contract in Brazil, marking the Company’s first subsea umbilical maintenance campaign in the world’s largest deepwater market. This first significant contract in Brazil represents a major step towards establishing KOIL as the preferred provider of subsea umbilical services throughout the region. The contract includes the re-termination and testing of umbilical elements including chemical injection and hydraulic control lines, as well as electrical cables. KOIL is utilizing proprietary methodology and specialized equipment to safely and efficiently perform the pull-in, removal, and replacement of new elements.

In September, the Operations Team successfully completed its first campaign utilizing our newly acquired mobile carousel. The 3,500-metric-ton modular offshore carousel system was deployed to transpool approximately 50 miles of subsea umbilical cable, which was then transported and transferred to our existing land-based carousel for long term storage. This successful first deployment demonstrates the expanded capabilities and flexibility the new equipment brings to our service offering.

Subsequent to September 30, 2026, KOIL announced that it had secured a significant contract for Subsea Cable Management Services where the Company will deploy a dedicated team of experienced service supervisors and technicians to provide operational support and coordination, including umbilical spooling and operations. The scope also includes specialized rental equipment and highlights KOIL’s ability to complement its subsea equipment offerings with experienced field service personnel and ongoing operational support.

To further expand KOIL’s global reach, the Company also announced a strategic alliance with Pipeline Network, a consultancy focused on the oil and gas pipeline services sector, designed to expand its international presence, operational capabilities, and customer support across the Eastern Hemisphere.

Demand forecasts continue to reinforce confidence in offshore markets, with the industry firmly in an upcycle. Sixty-three offshore final investment decisions (FIDs) have already been recorded in 2026, with another 26 expected by year-end, bringing the potential total to 89 compared with 57 in 2025. The subsea outlook also remains robust, with approximately 1,380 trees forecast through 2030 and award activity expected to accelerate over the next several years, according to market analysts.

The Company has renewed its growth strategy called “KOIL 2030,” which is a bold strategic roadmap focused on three pillars: 1) systems solution, 2) Brazilian expansion, and 3) rental equipment.

Shareholders can find a more detailed overview of the Company’s strategy by visiting the investor relations section of KOIL’s website.

Subsequent to the end of third quarter, on October 28, 2026, KOIL Energy proudly announced that it has entered into a securities purchase agreement with certain institutional and other accredited investors to raise approximately $5.6 million of gross proceeds through a private investment in public equity (“PIPE”) financing of common stock or common stock equivalents.

The financing is intended to support the next phase of the Company’s growth journey by allowing us to expand our rental equipment fleet and strengthen our service capabilities to better serve our customers.

KOIL will host an investor conference call to discuss its third quarter of 2026 results on Friday, November 13, 2026, at 9:00 am Eastern Time.

Interested parties may listen to the call through a webcast link or by dialing in. (See below for details.)

PARTICIPANT WEBCAST LINK:

https://edge.media-server.com/mmc/p/x2pceq5y

Participant Toll-Free Dial: 1-833-630-1956
Participant Toll/Int’l Dial: 1-412-317-1837
Conference Code: Koil Energy Solutions call

Replay Dials (valid for 7 days after the event)
  Replay Toll-Free: 1-855-669-9658
  Replay Toll: 1-412-317-0088

Replay Code: 8514985

The earnings release and a replay of the conference call will also be available on the Company’s website, www.koilenergy.com, under the “Investors” section.

About KOIL (www.koilenergy.com)

KOIL Energy is a leading energy services company offering subsea equipment and support services to the world’s energy and offshore industries. We provide innovative solutions to complex customer challenges presented between the production facility and the energy source. Our core services and technological solutions include distribution system installation support and engineering services, umbilical terminations, loose-tube steel flying leads, and related services. Additionally, KOIL Energy’s experienced team can support subsea engineering, manufacturing, installation, commissioning, and maintenance projects located anywhere in the world.

Forward-Looking Statements

Any forward-looking statements in the preceding paragraphs of this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties in that actual results may differ materially from those projected in the forward-looking statements. In the course of operations, we are subject to certain risk factors, competition and competitive pressures, sensitivity to general economic and industrial conditions, international political and economic risks, availability and price of raw materials and execution of business strategy. For further information, please refer to the Company’s filings with the Securities and Exchange Commission, copies of which are available from the Company without charge.

Investor Relations Contact:

ir@koilenergy.com
281-862-2201

KOIL ENERGY SOLUTIONS, INC.
SUMMARY FINANCIAL DATA
(UNAUDITED)
Comparative Condensed Consolidated Income Statement
	Three Months Ended September 30,								Nine Months Ended September 30,
(In thousands, except per share amounts)		2026				2025				2026				2025
Revenues	$	10,306			$	6,367			$	27,709			$	16,799
Cost of sales		7,532				4,315				19,342				11,341
Selling, general and administrative		2,327				2,514				6,974				6,220
Operating income (loss)		447				(462	)			1,393				(762	)
Total other (income) expense		(219	)			57				(221	)			403
Income (loss) before income tax expense		228				(405	)			1,172				(359	)
Provision for income tax		21				8				72				23
Net income (loss)	$	207			$	(413	)		$	1,100			$	(381	)
Net income (loss) per share, basic	$	0.02			$	(0.03	)		$	0.09			$	(0.03	)
Weighted-average shares outstanding, basic		12,502				12,169				12,318				12,115
Comparative Condensed Consolidated Balance Sheets
	September 30,				December 31,
(In thousands)		2026				2025
Assets:
Cash	$	561			$	1,535
Other current assets		14,355				8,410
PP&E, net		6,339				3,642
Other non-current assets		5,827				6,227
Total assets	$	27,082			$	19,814
Liabilities:
Current liabilities		11,497				5,140
Other long-term liabilities		4,998				5,711
Total liabilities		16,495				10,851
Stockholders’ equity		10,587				8,963
Total liabilities and stockholders’ equity	$	27,082			$	19,814
Adjusted EBITDA
	Three Months Ended September 30,								Nine Months Ended September 30,
(In thousands)		2026				2025				2026				2025
Net income (loss)	$	207			$	(413	)		$	1,100			$	(382	)
Add: Interest expense (income), net		174				–				182				(16	)
Add: Income tax expense		21				8				72				23
Add: Depreciation and amortization		238				146				597				449
Add: Share-based compensation		181				92				562				241
Add (Deduct): Loss (gain) on sale of asset		16				–				15				(12	)
Add: Loss (Gain) on Litigation Settlement		–				(84	)			–				(333	)
Add: Restructuring costs		–				–				–				279
Adjusted EBITDA	$	837			$	(251	)		$	2,528			$	249
Cash Flow Data
	Three Months Ended September 30,								Nine Months Ended September 30,
(In thousands)		2026				2025				2026				2025
Cash provided by (used in):
Operating activities	$	(748	)		$	(365	)		$	(1,055	)		$	(1,039	)
Investing activities		(2,904	)			(1,074	)			(2,914	)			(1,152	)
Financing activities		2,733				798				2,998				716
Change in cash	$	(919	)		$	(641	)		$	(971	)		$	(1,475	)

DENVER, Nov. 13, 2026 (GLOBE NEWSWIRE) — (247MarketNews) — NeOnc Technologies Holdings (NASDAQ: NTHI) reaches an important clinical-development milestone today as it presents updated findings from two investigational brain cancer programs at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO) in Philadelphia. The presentations put the company’s intranasal NEO100 and oral NEO212 programs in focus, with additional clinical evidence arriving as NeOnc prepares for important FDA discussions and continues to attract substantial insider buying.

The first presentation, abstract CTNI-26, titled Durable Radiographic Remission and Prolonged Survival with Intranasal NEO100 in Recurrent WHO Grade III/IV IDH1-Mutant Astrocytoma, provides updated Phase 1/2a and compassionate-use experience. Presented by Chief Medical Officer Thomas C. Chen, MD, PhD, the findings are particularly important because they build on previously reported survival and progression-free survival results in a difficult-to-treat patient population.

In August, NeOnc reported that its Phase 2a study achieved six-month progression-free survival of 48.9%, versus a prespecified historical benchmark of 20% (p=0.0047). Median overall survival was 26.1 months, with estimated survival of 86.7% at six months, 61.5% at 12 months and 54.7% at 24 months. The efficacy population included 24 patients, 21 with grade 4 and three with grade 3 IDH1-mutant astrocytoma. Five patients remained on treatment at the interim database lock.

The company reported no treatment-related Grade 3 or higher adverse events, treatment-related serious adverse events or discontinuations due to treatment-related adverse events. These results provide the clinical foundation for NeOnc’s effort to advance NEO100 toward a potential accelerated approval pathway.

The compassionate-use component provides an additional dimension. In October, NeOnc reported that a critically ill three-year-old boy receiving investigational NEO100 in Abu Dhabi began breathing independently without ventilator support and moving his legs, according to his treating physicians.

The second presentation, abstract CTNI-27, examines oral NEO212 in temozolomide-resistant recurrent glioblastoma and brain metastases. Its focus is Phase 1 safety, pharmacokinetics and early activity.

NEO212 combines temozolomide with perillyl alcohol in an oral formulation intended to improve drug delivery to the brain and address temozolomide resistance. NeOnc reports that Phase 1 dose escalation is complete, with no observed myelosuppression. The company also disclosed two objective responses: one in recurrent glioblastoma and another in a patient with lung-cancer brain metastasis. Both patients reportedly remained on treatment for more than 20 months.

These observations are particularly interesting given the hematologic toxicity associated with conventional temozolomide. NEO212 now represents a second potential clinical opportunity, distinct from NEO100’s intranasal delivery strategy.

NeOnc’s regulatory calendar is becoming increasingly important. The FDA granted a Type B End-of-Phase meeting scheduled for early January 2027 to discuss NEO100’s potential accelerated approval pathway, a proposed randomized Phase 3 trial and the adequacy of its nonclinical safety package. The proposed NEO100-012 study would compare intranasal NEO100 with investigator’s-choice chemotherapy, using overall survival as its primary endpoint.

NEO212 has its own upcoming regulatory milestone: an End-of-Phase 1 Type B FDA meeting scheduled for November 23. NeOnc intends to discuss patient populations, dosing, endpoints and a proposed randomized Phase 2 design covering brain metastases, IDH1-mutant astrocytoma and recurrent IDH1-wildtype glioblastoma.

The clinical developments coincide with continued insider buying. CEO Amir Heshmatpour reported approximately $333,100 in additional open-market purchases across 80,000 shares acquired November 9–11. His directly held position increased to 3,333,000 shares. Chief Medical Officer Chen also purchased 5,016 shares through his IRA for approximately $20,000. The latest activity brings reported 2026 insider purchases to approximately 341,000 shares.

Other factors adding to investor interest include four analyst Buy ratings, with reported price targets ranging from $13 to $20, and short interest exceeding 920,000 shares as of October 30, according to the market data.

International expansion is another developing opportunity. An October memorandum of understanding with the Department of Health – Abu Dhabi establishes a framework for CNS oncology research, clinical collaboration, training and real-world evidence, building on previously granted investigational authorizations for NEO100 and NEO212.

For investors, today’s SNO presentations matter because they bring two distinct clinical programs into the spotlight at the same time. The next tests are whether the updated NEO100 findings strengthen the case for further development, whether NEO212’s early safety and activity observations translate into controlled clinical evidence, and how the FDA responds to both development strategies.

About 247MarketNews

In today’s fast-moving markets, visibility is everything and 247MarketNews provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 247MarketNews delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 247MarketNews can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247MarketNews is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247MarketNews highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
247MarketNews
Editor@247marketnews.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

CALGARY, Alberta, Nov. 13, 2026 (GLOBE NEWSWIRE) — Inventronics Limited (“Corporation”) (IVX: TSX Venture), a designer and manufacturer of enclosures for the telecommunications, cable, electric distribution, energy, and other industries in Canada and the USA, today announced its unaudited 2026 Q3 financial results.

For the three months ended September 30, 2026, Inventronics reported profit of $156,000, or 3.2 cents per share, on sales of $2,509,000 compared to net earnings of $112,000, or 2.3 cents per share, on sales of $2,078,000 for the three months ended September 30, 2025. For the nine months ended September 30, 2026, Inventronics reported profit of $313,000, or 6.4 cents per share, on sales of $6,506,000 compared to profit of $433,000, or 8.9 cents per share, on sales of $6,695,000 for the comparative period in 2025.

Financial Highlights
	Three months ended		Nine months ended
(in thousands of dollars, except per share amounts)	Sept 30 2026	Sept 30 2025	Sept 30 2026	Sept 30 2025
Sales	2,509	2,078	6,506	6,695
Profit	156	112	313	433
Basic profit per share	3.2¢	2.3¢	6.4¢	8.9¢

Financial Position
As at (in thousands of dollars)		Sept 30 2026	Dec 31 2025
Working capital		1,087	1,761
Property, plant and equipment		3,992	3,149
Long-term debt, excluding current portion		1,891	2,050
Shareholders’ equity		2,909	2,581

Further information about the financial results of the Corporation can be found in the Corporation’s unaudited interim financial statements for the quarter ended September 30, 2026, and accompanying management’s discussion and analysis (“2026 Q3 MD&A”) filed on SEDAR+ at www.sedarplus.ca.

About Inventronics

Inventronics Limited designs and manufactures enclosures and other products for an array of customers in the telecommunications, cable, electric distribution, energy, and other industries in Canada and the USA. The Corporation owns its ISO 9001-registered production facility in Brandon, Manitoba.

Shares of Inventronics trade on the TSX Venture Exchange under the symbol “IVX”. For more information about the Corporation, its products and its services, go to www.inventronics.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Dan J. Stearne, President and CEO	(204) 717-0487	dstearne@inventronics.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

VANCOUVER, British Columbia, Nov. 13, 2026 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) a developer of marijuana, multi-drug, and alcohol breath testing technologies, is pleased to announce that its Chief Scientific Officer, Dr. Raj Attariwala, will be presenting the Company’s emerging multi-drug breath testing technology at the BC Centre for Excellence conference on substance use disorder being held in Vancouver, British Columbia on November 13.

The event is hosted by the BC Centre for Excellence, a world-renowned research and public health organization headed by Dr. Julio Montaner, whose pioneering treatments helped establish the global UNAIDS framework for combating HIV/AIDS. The conference will bring together physicians, researchers, addiction specialists, public health leaders and healthcare policy stakeholders to discuss current and emerging approaches to substance use disorder management, healthcare delivery and evidence-based public policy

During the presentation, Dr. Attariwala will discuss recent Cannabix findings demonstrating the ability of the Company’s Multi-Drug Breath Test platform to detect delta-9 THC and other illicit drugs in breath. These include the detection of traces of amphetamines/methamphetamines, cocaine, and opioids such as fentanyl. These findings highlight the broader potential of the Cannabix Breath Collection Unit (BCU) platform as a standardized breath collection technology that could support future multi-analyte testing approaches and scientific breath initiatives.

“We are pleased to be invited to this important forum and engage with leading clinicians, researchers and public health professionals working in the field of substance use disorders,” stated Dr. Raj Attariwala. “Breath testing represents an accepted non-intrusive method for drug detection, and we believe our technology platform can be a non-invasive and convenient method for collecting valuable biological information to support substance abuse monitoring programs and even be used to help identify new street drugs.”

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leading developer of breath-based technologies designed to enhance public safety and reduce impairment-related risks in workplaces, law enforcement, and a range of different settings. The Marijuana Breath Test (MBT) targets delta-9 THC—the primary psychoactive compound in cannabis—and other illicit drugs in breath, providing a practical solution for identifying recent drug use.

The BreathLogix, unmanned alcohol screening solution supports organizations in proactively monitoring alcohol impairment, strengthening safety protocols, and promoting responsible behavior. By delivering innovative, non-invasive screening tools, Cannabix aims to help reduce accidents, improve decision-making, and protect organizations, individuals and the public at large. Visit www.cannabixtechnologies.com

We seek Safe Harbor.
On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

Cautionary Statement Regarding Forward-Looking Statements

This news release contains certain “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). All statements in this release that are not purely historical in nature are forward-looking statements, including, without limitation, statements regarding: the significance of the Company’s fentanyl breath detection findings; the potential application of the Company’s Breath Collection Unit (“BCU”), Breath Cartridge technologies, and related analytical methods for multi-drug classes; the development of a broader multi-drug breath testing platform; potential commercial applications in workplace safety, transportation, substance-use disorder programs, pain management monitoring, forensic testing, law enforcement, and other markets; future research, validation studies, product development initiatives, regulatory developments, partnerships, commercial opportunities, and the Company’s ability to advance and commercialize its breath-based technologies. Forward-looking statements are often identified by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “project,” “seek,” “target,” “will,” and similar expressions, or statements that certain events or conditions “may” or “will” occur. These statements are based on management’s current expectations, assumptions, and beliefs in light of available information and are subject to a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, without limitation: the ability to replicate or further validate fentanyl detection results; limitations associated with breath-based drug testing technologies; uncertainty regarding scientific acceptance and market adoption of breath testing for fentanyl or other substances; regulatory requirements and approvals; the availability and performance of laboratory partners and other third-party service providers; intellectual property risks; technological and product development challenges; competition; changing market conditions; the availability of financing; and other risks that may affect the Company’s business, operations, and development plans. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results may differ materially from those anticipated in such statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update or revise them except as required by applicable securities laws.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.